Seagen and sanofi announce collaboration to develop and commercialize multiple novel antibody-drug conjugates

Bothell, wash. & paris--(business wire)--seagen inc. (nasdaq:sgen) and sanofi today announced an exclusive collaboration agreement to design, develop, and commercialize antibody-drug conjugates (adcs) for up to three cancer targets. the collaboration will utilize sanofi's proprietary monoclonal antibody (mab) technology and seagen's proprietary adc technology. adcs are antibodies engineered to deliver potent anti-cancer drugs to tumor cells expressing a specific protein and sanofi currently has
SGEN Ratings Summary
SGEN Quant Ranking